Statistical analysis of episensitization using transition probability functions and PFS2 for “ROCKET”, a two stage phase II study of RRx-001, a multi-epigenetic agent, investigating resensitization to irinotecan in colorectal cancer.

Authors

null

Nacer Abrouk

Innovexe, LLC, Mountain View, CA

Nacer Abrouk , Tony R. Reid , George A. Fisher , Corey Allan Carter , Paul M. Thambi , Bryan Oronsky , Gary Fanger , Scott Caroen , Christopher Parker , Meaghan Stirn , Jan Scicinski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02096354

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS775)

DOI

10.1200/jco.2016.34.4_suppl.tps775

Abstract #

TPS775

Poster Bd #

O6

Abstract Disclosures

Similar Posters